Logo.png
Vyant Bio Engages LifeSci Capital to Explore Strategic Alternatives
04 janv. 2023 16h15 HE | Vyant Bio, Inc.
CHERRY HILL, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Logo.png
Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at Neuroscience 2022 Hosted by the Society for Neuroscience
16 nov. 2022 17h05 HE | Vyant Bio, Inc.
“Targeting specific functional rescue in a Rett patient cortical organoid disease model” CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq:...
Logo.png
Vyant Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
16 nov. 2022 16h43 HE | Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Logo.png
Vyant Bio Reports Third Quarter 2022 Results and Provides Strategic and Business Highlights
15 nov. 2022 08h00 HE | Vyant Bio, Inc.
Q3 2022 and Recent Scientific and Business Highlights Completed the sale of its vivoPharm subsidiary to Reaction Biology Corporation for $5.5 million in an upfront cash paymentDelivered...
Logo.png
Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou Foundation
10 nov. 2022 17h13 HE | Vyant Bio, Inc.
CHERRY HILL, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex...
Logo.png
Vyant Bio Teams Up with the International Rett Syndrome Foundation to Host Local Viewing Party in Honor of the 3rd Annual ‘Raise a Glass for Rett Gala’
07 nov. 2022 09h00 HE | Vyant Bio, Inc.
Charity Event to Drive Awareness and Support Rett Families Around the World CHERRY HILL, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an...
Logo.png
Reaction Biology and Vyant Bio Announce Closing of Definitive Agreement to Acquire U.S. Operations of Vyant Bio, Inc. Subsidiary
03 nov. 2022 09h10 HE | Vyant Bio, Inc.
~ Reaction Biology Acquires the Hershey, Pennsylvania-Based U.S. Operations of Vyant Bio Subsidiary vivoPharm PTY Ltd. ~ ~ Transaction Expands Reaction Biology’s Capabilities to Provide Customers...
Logo.png
Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022
27 oct. 2022 17h10 HE | Vyant Bio, Inc.
Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD) CHERRY HILL, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Vyant...
Logo.png
Vyant Bio to Present at the LD Micro Main Event XV on Wednesday, October 26, 2022
24 oct. 2022 16h15 HE | Vyant Bio, Inc.
-To Discuss its Novel Drug Discovery Platform that is Accelerating the Process of Finding Cures for Neurogenerative Diseases CHERRY HILL, N.J., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc....
Logo.png
Vyant Bio to Deliver a Live Presentation at the Skyline Signature Series™ on Thursday, September 8, 2022
01 sept. 2022 08h00 HE | Vyant Bio, Inc.
-Invites individual and institutional investors, as well as advisors and analysts, to attend this real-time, interactive presentation at the Skyline Signature Series™ CHERRY HILL, N.J., Sept. 01,...